When twelve PR3 ANCA assays were compared using 22 IBD sera, the reported prevalence of PR3-ANCA ranged from 4% to 43%, raising concerns as to the reliability of the assays used in these studies [44, 91–93]. This evidence concerns the gene PRTN3 and inflammatory bowel disease.